Status:
COMPLETED
Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Healthy
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
This study is being performed to evaluate a single 60 Mcg dose of lyophilized formulation of Merck Staphylococcus aureus vaccine (V710) in healthy subjects. This study is intended to provide necessary...
Eligibility Criteria
Inclusion
- 18 to 80 years of age
- Good physical health based upon medical history and physical examination
- Willing and able to participate in the entire study duration
- Female subject with a negative urine pregnancy test immediately prior to study vaccination
Exclusion
- Chronic skin infections or a chronic skin condition (e.g. psoriasis)
- Serious S. aureus infection in the last 12 months
- Allergy to aluminum-containing substance taken in the body or to any other vaccine component
- Oral temperature equal to or greater than 100.4ºF (38.0ºC), within the past 2 days
- Participation in a prior V710 vaccine clinical study
- Participation in any other clinical study in the past 4 weeks, or during the 3-month study duration
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00822757
Start Date
August 1 2007
End Date
December 1 2007
Last Update
October 2 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.